Value assessment frameworks are a relatively new concept designed to help stakeholders determine what treatments provide the most value in healthcare. They are sometimes influential in determining what therapies are chosen by patients and their doctors, and often used to determine if those therapies will be covered and reimbursed by payers. How these frameworks consider personalized medicine is not yet clear. Designed before 25% of all new drugs were personalized medicines, value frameworks might need to evolve to keep pace with scientific discovery and recognize the leading role of diagnostic testing in targeting therapeutic use. This session will examine how value assessment frameworks have been developed historically, examine the current critiques of their processes and methodologies and explore how they might have to change in the future to support personalized medicine.